# S2 Genomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/s2-genomics

- Industry: Biotechnology
- Headquarters: Livermore, US
- Website: www.s2genomics.com/
- Total disclosed funding: $16M
- Latest round: Series A (Jan 23, 2024)
- Investors on record: 2

## About

Established in 2016 and based in California, US, S2 Genomics, Inc. provides digital solutions that facilitate single-cell research with automation. As of 2023, the company is headed by its CEO Jonathan Schimmel. The company was founded by Stevan Jovanovich. In January 2024, the firm raised USD 16 million in Series A funding from investors BroadOak Capital Partners and Research Corporation Technologies.

The business offers an automated digital system for splitting raw tissues into individual cells or nuclei for research in cell biology and genetics. The firm product range includes Singulator 100, Singulator 200, NIC + Small Sample Cartridge, and RNase Inhibitor.

The company plans to use the January 2024 funding to accelerate the commercialization of its singulator platform.

## Funding rounds

- Series A, Jan 23, 2024, $16M — Research Corporation Technologies, BroadOak Capital Partners

## Investors

- Research Corporation Technologies (https://capitalatlas.ai/funds/research-corporation-technologies) — Series A
- BroadOak Capital Partners (https://capitalatlas.ai/funds/broadoak-capital-partners) — Series A